Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL229P is a human pseudogene belonging to the 7SL RNA family. The original 7SL RNA (such as RNA, 7SL, cytoplasmic 1, or RN7SL1) functions as an essential scaffold within the signal recognition particle (SRP), a ribonucleoprotein complex that mediates cotranslational protein targeting to the endoplasmic reticulum[3][5]. However, RN7SL229P, like most 7SL RNA-derived pseudogenes, is a truncated, non-functional copy resulting from the integration of sequence reverse-transcribed from RNA back into the genome[1]. RN7SL229P does not produce a functional RNA, is not expressed as a protein, and lacks documented biological or pathological significance. In rare cases, some pseudogenes act as competitive endogenous RNAs (ceRNAs) affecting gene regulation, but RN7SL229P is not known to have such a role[2][6]. Summary: RN7SL229P is a non-functional pseudogene derived from the 7SL RNA gene family, not a recognized therapeutic target or disease-associated biomolecule, with no established biological functions, disease roles, or pharmacological relevance[1][2][6].
None. RN7SL229P does not encode a functional molecule amenable to a therapeutic mechanism of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 229, pseudogene (RN7SL229P).